Moderate

Familial hypercholesterolaemia

Inherited severe LDL elevation · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Familial hypercholesterolaemia is an inherited disorder of LDL-receptor handling causing lifelong very high LDL-C and premature atherosclerosis. Early diagnosis using clinical criteria and aggressive LDL lowering dramatically reduce cardiovascular risk.

Red flags

  • LDL-C >13 mmol/L suggesting homozygous FH
  • Premature coronary disease in the patient or a young relative
  • Aortic stenosis murmur (supravalvular/valvular involvement in HoFH)
  • Tendon xanthomata or corneal arcus before age 45
  • Recurrent cardiovascular events despite treatment

Assessment

Differential diagnosis

  • Polygenic hypercholesterolaemia
  • Secondary hyperlipidaemia (hypothyroidism, nephrotic, cholestasis)
  • Familial combined hyperlipidaemia
  • Sitosterolaemia
  • Lipoprotein(a) elevation
  • Drug-induced dyslipidaemia

Investigations

  • Fasting lipid profile (LDL-C often >5 mmol/L untreated)
  • Exclude secondary causes: TSH, glucose, renal/liver function, urine protein
  • Lipoprotein(a) level once in a lifetime
  • Clinical scoring (Dutch Lipid Clinic or Simon Broome criteria)
  • Genetic testing for LDLR, APOB, PCSK9 variants
  • Cascade screening of first-degree relatives

Management

  • Suspect FH with very high LDL-C, tendon xanthomata or premature CAD family history
  • Apply a validated diagnostic score and exclude secondary causes
  • Arrange genetic testing and cascade screening of relatives
  • Set an LDL-C target of <2.6 mmol/L (primary prevention) or <1.4 mmol/L (established CVD)
  • Start high-intensity statin at maximum tolerated dose
  • Add ezetimibe early if target not reached
  • Add a PCSK9 inhibitor or inclisiran when still above target
  • Consider bempedoic acid in statin intolerance
  • Reinforce lifestyle: diet, exercise, smoking cessation
  • Assess and treat other risk factors aggressively
  • Consider lipoprotein apheresis in homozygous or refractory severe cases
  • Plan lifelong follow-up and family screening

Drugs & doses

Rosuvastatin 20-40 mg PO OD (or atorvastatin 40-80 mg OD)
Ezetimibe 10 mg PO OD
Alirocumab 75-150 mg SC every 2 weeks (or evolocumab 140 mg SC every 2 weeks)
Inclisiran 284 mg SC at 0 and 3 months then 6-monthly
Bempedoic acid 180 mg PO OD if statin intolerant
Evinacumab (ANGPTL3 inhibitor) IV for homozygous FH in specialist settings

Disposition

Refer to a lipid clinic; coordinate family cascade screening. Specialist apheresis/genetics for homozygous or refractory disease.

Complications & pitfalls

  • Premature coronary artery disease
  • Aortic valve and root atherosclerosis
  • Peripheral and carotid atherosclerosis
  • Statin intolerance limiting therapy
  • Under-treatment of relatives without screening

Exam pearls

  • Diagnosis should trigger cascade screening of all first-degree relatives
  • LDL-C does not need to be fasting for diagnosis in most cases
  • Homozygous FH presents in childhood and needs specialist lipid-clinic care
  • PCSK9 inhibitors and inclisiran offer major additional LDL lowering
  • Lp(a) should be measured once as it modifies risk independently

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.